EndoChoice Holdings (ECPM Holdings)

General Information

We are a medical device company focused exclusively on designing and commercializing a platform of innovative products and services for gastrointestinal, or GI, caregivers. We currently serve over 2,500 GI departments that perform endoscopic procedures, which represent approximately one-third of the U.S. market. We offer a comprehensive range of products and services that span single-use devices and infection control products, pathology and imaging systems. In December 2013, we began limited commercialization of our Fuse® full spectrum endoscopy system, or Fuse®. Our Fuse® system enables GI specialists to see more than twice the anatomy at any one time compared to standard, forward-viewing colonoscopes and has been clinically demonstrated to detect 69% more pre-cancerous polyps than standard colonoscopes. We believe our commitment to continuing innovation and focus on GI specialists provides us with the unique capability to meet their evolving needs. We intend to leverage our broad product platform, established customer relationships, commercial infrastructure and Fuse® technology to set a new standard of care for the global GI market.

Employees: 418
Founded: 2007
Contact Information
Address 11810 Wills Road, Alpharetta, GA 30009, US
Phone Number (888) 682-3636
Web Address http://www.endochoice.com
View Prospectus: EndoChoice Holdings (ECPM Holdings)
Financial Information
Market Cap $367.5mil
Revenues $64.3 mil (last 12 months)
Net Income $-63.2 mil (last 12 months)
IPO Profile
Symbol GI
Shares (millions): 6.4
Price range $15.00 - $15.00
Est. $ Volume $95.3 mil
Manager / Joint Managers J.P. Morgan/ BofA Merrill Lynch/ William Blair/ Stifel
CO-Managers -
Expected To Trade: 6/5/2015
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change